Synergistic growth inhibition by combination of adenovirus mediated p53 transfer and cisplatin in ovarian cancer cell lines

다국어 초록 (Multilingual Abstract)

Objective: This study was to investigate the synergistic growth inhibitory effect by combination of adenovirus
mediated p53 gene transfer and cisplatin in ovarian cancer cell lines with different p53 gene mutation patterns.
Methods: Three ovarian cancer cell lines, p53 deleted SKOV3, p53 mutated OVCAR-3, and PA-1 with wild-type p53
were transduced with human adenovirus vectors carrying p53 gene (Ad-p53) and treated with a sublethal concentration
of cisplatin before and after Ad-p53. The cell number was counted daily for 5 days after Ad-p53 transduction.
Western blotting was used to identify p53 and p21 protein expressions, and flow cytometric analysis was performed
to investigate any change of DNA ploidy after Ad-p53 transfer.
Results: Ad-p53 transduced cells successfully expressed p53 and p21 proteins after 48 hours of Ad-p53 transduction.
Synergistic growth inhibition by combination of Ad-p53 and cisplatin was detected only in SKOV3 and OVCAR-3
cells, but not in PA-1 cells. In p53 deleted SKOV3 cells, cisplatin treatment after Ad-p53 showed higher growth
inhibition than the treatment before Ad-p53 transduction, and reverse relationship was observed in p53 mutated
OVCAR-3 cells. In SKOV3 cells, the fraction of cells at G2/M phase increased after cisplatin treatment, however, it
decreased dramatically with Ad-p53 transduction.
Conclusion: The synergistic growth inhibition by combination of Ad-p53 and cisplatin may depend on the p53 status
and the temporal sequence of cisplatin treatment, suggesting judicious selective application of this strategy in clinical
trials.

참고문헌 (Reference)

• 1 Kupryjanczyk J, "p53 gene mutations and protein accumulation in human ovarian cancer" 90 : 4961-4965, 1993
• 2 Yang B, "Wild-type p53 protein potentiates cytotoxicity of therapeutic agents in human colon cancer cells" 2 : 1649-1657, 1996
• 3 Waldman T, "Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21" 381 : 713-716, 1996
• 4 Hamada M, "The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers" 122 : 360-365, 1996
• 5 Kohler MF, "Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer" 85 : 1513-1519, 1993
• 6 Roth JA, "Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer" 2 : 985-991, 1996
• 7 Bunz F, "Requirement for p53 and p21 to sustain G2 arrest after DNA damage" 282 : 1497-1501, 1998
• 8 Kastan MB, "P53, cell cycle control and apoptosis: implications for cancer" 14 : 3-15, 1995
• 9 Ozols RF, "Ovarian cancer, fallopian tube carcinoma, and peritoneal carcinoma. in: Cancer: Principle and practice of oncology. 5th ed" Lippincott-Raven Publishers 1502-1539, 1997
• 10 Ogawa N, "Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agent" 73 : 367-370, 1997
• 11 Williams GT, "Molecular regulation of apoptosis: Genetic controls on cell death" 74 : 777-779, 1993
• 12 Berchuck A, "Molecular genetic features of ovarian cancer" 394 : 269-284, 1996
• 13 Sambrook J, "Molecular cloning: a laboratory manual. 2nd ed" Cold Spring Harbor Laboratory Press 1989
• 14 Hamilton TC, "Molecular biology of gynecologic malignancies. in: Gynecologic oncology. 1st ed" Kluwer Academic Publisher 103-114, 1998
• 15 Roemer K, "Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function" 716 : 265-280, 1994
• 16 Fujiwara T, "Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene" 54 : 2287-2291, 1994
• 17 Shaw P, "Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line" 89 : 4495-4499, 1992
• 18 von Gruenigen VE, "In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer" 69 : 197-204, 1998
• 19 Eastham JA, "In vivo gene therapy with p53 or p21 adenovirus for prostate cancer" 55 : 5151-5155, 1995
• 20 Zhang WW, "High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus" 1 : 5-13, 1994
• 21 Randomised comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer, "Gruppo Interegionale Cooperativo Oncologico Ginecologia" 2 : 353-359, 1987
• 22 Chen PL, "Genetic mechanisms of tumor suppression by the human p53 gene" 250 : 1576-1580, 1990
• 23 Duesberg P, "Genetic instability of cancer cells is proportional to their degree of aneuploidy" 95 : 13692-13697, 1998
• 24 Polyak K, "Genetic determinants of p53-induced apoptosis and growth arrest" 10 : 1945-1952, 1996
• 25 Nguyen DM, "Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirusmediated p53 gene transfer" 112 : 1372-1376, 1996
• 26 Skehan P, "Cytotoxicity and cell growth assays. in: Cell biology. 2nd ed" Academic Press 313-318, 1998
• 27 Graham FL, "Characteristics of a human cell line transformed by DNA from human adenovirus type 5" 36 : 59-74, 1977
• 28 Juan G, "Cell cycle analysis by flow and laser scanning cytometry. in: Cell biology. 2nd ed" Academic Press 261-274, 1998
• 29 Pecorelli S, "Carcinoma of the ovary" 3 : 75-102, 1998
• 30 Tang DC, "Butyrate-inducible and tumor-restricted gene expression by adenovirus vectors" 1 : 15-20, 1994
• 31 McGuire WP, "Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study" 13 : 1589-1599, 1995
• 32 Mujoo K, "Adenoviralmediated p53 tumor suppressor gene therapy of human ovarian carcinoma" 12 : 1617-1623, 1996
• 33 Yaginuma Y, "Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines" 52 : 4196-4199, 1992
• 34 Kanegae Y, "A simple and efficient method for purification of infectious recombinant adenovirus" 47 : 157-166, 1994
• 35 Cross SM, "A p53-dependent mouse spindle checkpoint" 267 : 1353-1356, 1995
• 36 Kanamori Y, "A newly developed adenovirus-mediated transfer of a wildtype p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells" 34 : 1802-1806, 1998